Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Patent
1995-08-30
1998-05-12
Ketter, James
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
514 2, 514 29, A61K 3855
Patent
active
057504938
ABSTRACT:
Methods for improving the cellular uptake of protease inhibitors (e.g., HIV protease inhibitor), alone or in the presence of one or more additional therapeutic agents, in protease inhibitor-based therapies, involving administration of one or more AAG-binding compounds, such as macrolide or lincosamide antibiotics, which have sufficient binding affinity for AAG to competitively bind AAG in the presence of the protease inhibitor.
REFERENCES:
Copy of written opinion in corresponding PCT Application No. PCT/US96/13721.
Bilello et al, "Reduction of the In Vitro Activity of A77003, an Inhibitor of Human Immunodeficiency Virus Protease, by Human Serum .alpha..sub.1 Acid Glycoprotein", The Journal of Infectious Diseases 1995: 171:546-551.
Dette et al, "The Binding Protein of Erythromycin in Human Serum", Biochemical Pharmacology, vol. 35, No. 6, pp. 959-966.
Kageyama et al, "Protein Binding of Human Immunodeficiency Virus Protease KNI-272 and Alteration of Its In Vitro Antiretroviral Activity in the Presence of High Concentrations of Proteins", Antimicrobial Agents and Chemotherapy, May 1994, pp. 1107-1111.
Chatterjee et al, "Reversal of Multidrug Resistance by Verapamil and Modulation by .alpha..sub.1 -Acid Glycoprotein in Wild-type and Multidrug-resistant Chinese Hamster Ovary Cell Lines", Cancer Research 50, 2818-2822, May 1, 1990 and attached Abstract.
Chatterjee et al, "Reversal of Acquired Resistance to Adriamycin in CHO Cells By Tamoxifen and 4-Hydroxy Tamoxifen: Role of Drug Interaction of Alpha 1 acid Glycoprotein", Br J Cancer, Nov. 1990, 62(5), 712-717 and Attached Abstract.
Urien et al, "ph-Dependency of Basic Ligand Binding to .alpha..sub.1 -Acid Glycoprotein (Orosomucoid)", Biochem. J., (1991) 280, 277-280 and attached Abstract.
Chatterjee et al, "Enhancement of Adriamycin Cytotoxicity in a Multidrug Resistant Chinese Hamster Ovary (CHO) Ssubline, CHO-Adrr, By Toremifene and Its Modulation of Alpha 1 Acid Glycoprotein", Eur J. Cancer, Apr. 1990, 26(4) 432-436 and attached Abstract.
Abstract: Barre et al., "Pharmacokinetics of erythromycin In Patients With Severe Cirrhosis", Br J. Clin Pharmacol, Jun. 1987, 23(6), pp. 753-757.
Abstract: Qin et al., "Decreased Elimination of Drug in the presence of Alpha-1-Acid Glcyprotein is Related to a Reduced Hepatocyte Uptake", J Pharmcol Exp Ther, Jun. 1994, 269(3), PP. 1176-1181.
Abstract; Heikinheimo et al, "Dose-Responce Relationships of RU 486", Ann Med, Feb. 1993, 25(1), pp. 71-76.
Abstract: Maruyama et al, "Characterization of Drug Binding Sites on Alpha 1-Acid Glcyprotein", Chem Pharm Bull, Jun. 1990, 38(6), pp. 1688-1691.
Abstract: Prandota et al, "Binding of Erythromycin Base to Human Plasma Proteins", J Int Med Res, 1980, 8 Suppl 2, pp. 1-8.
Wanwimolruk et al, "Plasma Protein Binding of Quinine: Binding to Human Serum Albumin, Alpha 1-Acid", J Pharm Pharmacol, Oct. 1992, 44(10) pp. 806-811 and attached Abstract.
Periti et al, "Pharmacokinetic Drug Interactions of Macrolides", m Clin. Pharmacokinet. 23(2)l 106-131, 1992.
Rodvold et al, "New Oral Macrolide and Fluoroquinolone Antibiotics: An Overview of Pharmacokinetics, Interactions, and Safety", Chemotherapy, Clinical Infectious Diseases 1993: 17(Suppl 1):S192-9.
Periti et al, "Clinical Pharmacokinetic Properties of the Macrolide Antibiotics (Part I)", Clinical Pharmacokentics 16: 193-214 (1989).
Periti et al, "Clinical Pharmacokinetic Properties of the Macrolide Antibiotics (Part II)", Clinical Pharmacokinetics 16: 261-282 (1989).
Kremer et al, "Drug Binding to Human Alpha-1-Acid Glcyprotein In Health and Disease", Pharmacological Reviews, (1988), vol. 40, No. 1, pp. 1-47.
"Drug Binding to Alpha 1 Acid Glcyprotei -Clinically Important?" (editorial), Lancet, Feb. 18, 1979, 1(8112), p. 368 and attached Abstract.
Chiang et al, Phamacological Activity of Prazosin is decreased by Alpha-1-Acid Glcyprotein in Vivo, J. Pharmacol Exp Ther, Jul. 1990, 254(1), pp. 324-349 and attached Abstract.
Chang "Progress and Prospects in Protease Inhibitor Research", Journal of the Physicians Assn for AIDS Care, Jul. 1994, pp. 8-15.
Condra et al, "In Vivo Emergence of HIV-1 Variants Resistant to Multiple Protease Inhibitors", Nature, vol. 374, Apr. 6, 1995, pp. 569-571.
McKerrow et al, "The Protease and Pathogenicity of Parasitic Protozoa.sup.1 ", Annu. Rev. Microbiol., 1993, 47:821-53.
Richman, "Protease Unhibited", New and Views, Nature, vol. 374, Apr. 5, 1995.
Schinazi Raymond F.
Sommadossi Jean-Pierre
Brusca John S.
Ketter James
Schinazi Raymond F.
University of Alabama at Birmingham
LandOfFree
Method to improve the biological and antiviral activity of prote does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to improve the biological and antiviral activity of prote, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to improve the biological and antiviral activity of prote will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-979067